Current perspectives in the pharmacological combination treatment for low-grade serous ovarian cancer. (PubMed, Expert Opin Pharmacother) - Oct 17, 2026 - "MAPK signaling represents the principal molecular vulnerability: trametinib provides the strongest randomized evidence in recurrent disease, while avutometinib plus defactinib is approved in the United States for previously treated KRAS-mutated LGSOC. Emerging strategies include combined pathway inhibition, chemotherapy-sparing endocrine regimens, and antibody-drug conjugates directed against FRα and TROP2. Their future integration will require prospective biomarker validation and direct comparison with established active treatments."
Journal • Review • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • CDK4 • ER • FOLR1 • KRAS
|
|
Alessandro D Santin; Cem Demirkiran; Kathrine Cooke; Namrata Sethi; Oda Fløtre Kvile; Orazio de Tommasi; Stefania Bellone; Stirling Wallace; Tobias M P Hartwich
|